Author

D. Provencher

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Approach:experimental assay· 3 Research Focus:differential expression· 2 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1 Research Focus:clustering· 1

Frequent Co-Authors

A.-M. Mes-Masson· 4 shared F. Rodier· 3 shared I. Clement· 3 shared K. Rahimi· 3 shared M. Skulimowski· 3 shared E. Carmona· 2 shared J. Lafontaine· 2 shared L. Communal· 2 shared

Activity by Year

2018-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A.-M. Mes-Masson

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Gravity-based microfiltration reveals unexpected prevalence of circulating tumor cell clusters in ovarian and colorectal cancer

A. Meunier, J. A. Hernandez-Castro, N. Chahley, L. Communal, S. Kheireddine, N. Koushki, N. Davoudvandi, S. Al Habyan, B. Peant, A. Lazaris, A. Ng, T. Veres, L. McCaffrey, D. Provencher, P. Metrakos, , D. Juncker

This study introduces gravity-based microfiltration to isolate CTC clusters, finding they are prevalent in ovarian and colorectal cancer patients.

bioRxiv · Dec 5, 2023Bioengineering

A senescence-like state is beneficial for ovarian cancer treatment

M. Skulimowski, L. Calvo Gonzalez, S. Cheng, I. Clement, L. Portelance, Y. Zhan, E. Carmona, J. Lafontaine, M. Deladurantaye, K. Rahimi, D. Provencher, A.-M. Mes-Masson, F. Rodier

This study shows that senescence in ovarian cancer cells after chemotherapy correlates with better patient survival, suggesting senescence could be a therapeutic target.

bioRxiv · Sep 30, 2023 · PreprintCancer Biology

53BP1 mediates sensitivity to chemotherapy and is associated with poor clinical outcomes in high-grade serous ovarian cancer

M. Skulimowski, J. Bourbonnais, N. Malaquin, H. Fleury, I. Clement, L. Communal, K. Rahimi, D. Provencher, A.-M. Mes-Masson, F. Rodier

This study shows that high 53BP1 levels in ovarian cancer are linked to poor survival and chemotherapy resistance, suggesting it could be a therapeutic target.

bioRxiv · Sep 30, 2023 · PreprintCancer Biology

Cellular senescence is a central response to cytotoxic chemotherapy in high-grade serous ovarian cancer

L. Calvo, S. Cheng, M. Skulimowski, I. Clement, L. Portelance, Y. Zhan, E. Carmona, J. Lafontaine, M. de Ladurantaye, K. Rahimi, D. Provencher, A.-M. Mes-Masson, F. Rodier

The paper shows that chemotherapy induces cellular senescence in high-grade serous ovarian cancer, which correlates with better patient survival.

bioRxiv · Sep 24, 2018 · PreprintCancer Biology